The hybrid compounds consisting of 4-aminoquinoline and 4-thiazolidinone are developed, utilizing molecular docking for sorting, followed by synthesis and evaluation of their anti-malarial potential and the scaffold may be a good lead for the development of next-generation antimalarials.
Abstract
Introduction Molecular hybridization is an effective approach employed to synthesize molecules that possess the ability to function as dual inhibitors, thereby addressing the issue of growing resistance. Resistance by the malaria parasite is one such example. Therefore, the study aims to develop hybrid compounds consisting of 4-aminoquinoline and 4-thiazolidinone, utilizing molecular docking for sorting, followed by synthesis and evaluation of their anti-malarial potential. Methods The molecules were selected on the basis of affinity from the computational study. To strengthen the in silico docking, a 200ns molecular dynamics simulation study was also performed. The title compounds, 7-18, were synthesized in a three-step reaction, involving non-polar solvent addition reaction resulting in heterocyclization. The synthesis was followed by characterization of all the synthesized compounds, and they were further subjected to biological screening through in-vitro, and the selected actives to in-vivo evaluation. An acute toxicity study was also conducted. Results The compounds exhibited promising action, with five compounds, 8, 9, 14, 15, and 18, demonstrating efficacy comparable to the reference drug in the Pf-DHFR enzyme inhibition assay. Four of the active compounds selected for the Plasmodium berghei murine model displayed excellent activity, with percentage parasitaemia inhibition to the extent of 84%, and mean survival time up to 27 days. The MD simulation study showed the stability of the ligand-protein complex up to 200 ns. The in silico ADMET prediction, along with acute toxicity testing of the most active compound, showed no major toxicity. Discussion The study concludes the hybrid compounds to be promising antimalarial agents, and the scaffold may be a good lead for the development of next-generation antimalarials.
Abstract The 1,2,4-triazole nucleus is a privileged scaffold in medicinal chemistry, as it is present in many clinically approved antifungal, anticancer and antiviral agents. However, the development of new triazole-based derivatives with better potency and safety profiles is demanded due to the emergence of antimicrob...
Ahmed M. Abobakr, Rasha A. Nabil, H. H. Temirek et al.· Polycyclic aromatic compound...· 0 citations
The results indicate that the thiazole-benzodioxole scaffold is a promising framework for developing multifunctional agents with combined neuroprotective, antidiabetic, and antioxidant activities.
Tuğçe Çaklılı, Yusuf Sıcak, Somdatta Y. Chaudhari et al.· Pharmaceuticals· 0 citations
The seven thiosemicarbazones containing pyrazole frame 2a–g have been synthesized under catalyst-free condition. All the compounds have been characterized by means of nuclear magnetic resonance, and mass spectrometric data. The antimicrobial efficacy was evaluated in vitro against Gram-positive and Gram-negative bacter...
Ashwini L. Jakkawad, Rameshwar M. More, Archana B. Kadam et al.· Organic Communications· 0 citations
Metronidazole is a well-known Nitroimidazole drug with comprehensive antibacterial action. In this study, a series of novel Metronidazole-substituted 3,4-dihydropyrimidinones (
3a–3j
) were synthesized via a modified Biginelli reaction to explore their potential as antibacterial agents. The newly synthesized comp...
Mojtaba Nouri, K. A. Dilmaghani, Z. Mardani· Scientific Reports· 0 citations
INTRODUCTION
To examine the design, synthesis, and pharmacological potential of novel artemisinin-isatin hybrid compounds as a strategy to overcome drug resistance and expand therapeutic applications beyond malaria.
METHODS
Researchers employed molecular hybridization techniques-specifically Cu-promoted azide-alkyne...
Vishal Choudhary, Aanya Saini, Emmanuel F. Freeman et al.· Mini-Reviews in Medical Chem...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.